Alkermes plc
ALKS
Classement en actions
#2587
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Prix de l'action
$44.48
Capitalisation boursière
$7.46B
Changement (1 jour)
3.50%
Changement (1 an)
43.56%
Pays
IE
Échange Alkermes plc (ALKS)
Catégorie
Healthcare
Revenus pour Alkermes plc (ALKS)
Revenus en Jun 2026 TTM : $1.67B
Selon les derniers rapports financiers de Alkermes plc, le chiffre d'affaires actuel de l'entreprise (TTM) est de $1.67B. En 2023, l'entreprise a réalisé un chiffre d'affaires de $1.66B une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $1.11B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Alkermes plc de 2000 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $1.67B | 7.06% |
| 2024 | $1.56B | -6.36% |
| 2023 | $1.66B | 49.61% |
| 2022 | $1.11B | -5.28% |
| 2021 | $1.17B | 13.00% |
| 2020 | $1.04B | -11.29% |
| 2019 | $1.17B | 7.01% |
| 2018 | $1.09B | 21.13% |
| 2017 | $903.37M | 21.15% |
| 2016 | $745.69M | 18.68% |
| 2015 | $628.34M | 1.54% |
| 2014 | $618.79M | 7.51% |
| 2013 | $575.55M | 0.00% |
| 2012 | $575.55M | 47.59% |
| 2011 | $389.98M | 108.95% |
| 2010 | $186.64M | 4.69% |
| 2009 | $178.28M | -45.45% |
| 2008 | $326.84M | 35.78% |
| 2007 | $240.72M | 0.31% |
| 2006 | $239.97M | 44.04% |
| 2005 | $166.60M | 118.85% |
| 2004 | $76.13M | 94.92% |
| 2003 | $39.05M | -17.37% |
| 2002 | $47.27M | -12.63% |
| 2001 | $54.10M | -3.44% |
| 2000 | $56.03M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 657.01% |
US
|
|
| $2.23B | 33.60% |
US
|
|
| $15.74B | 844.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 261.06% |
NL
|
